Clinical trials: Idiopathic Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
Tezosentan in Pulmonary Arterial Hypertension
Multicenter, Open-label, Non-comparative, Proof-of-concept, Phase 2a Study to Evaluate the Effect of a Single Infusion of Tezosentan on Pulmonary Vascular Resistance in Patients With Stable, Chronic Pulmonary Arterial…
- Trial name
- NCT01077297
- Testing
- Tezosentan
- Where
- 5 sites in United States, France and 1 more
- Volunteers
- 3 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Pulmonary Arterial Hypertension
miRNA and Myokines in Patients With PAH
The overall objective of this study is to fulfill the Pilot study (miRNA and Myokines Acutely-expressed During Exercise) goal to Investigate the excretion of skeletal muscle-derived miRNA and myokines in patients with pulmonary…
- Trial name
- NCT03905083
- Testing
- Exercise Rehab
- Where
- United States
- Sponsor
- University of Pittsburgh
Pulmonary Arterial Hypertension
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
Researchers are looking for more ways to treat PAH. In PAH, the blood vessels in the lungs become thick and narrow, which makes it harder for blood to flow. This causes high blood pressure in the lungs and overworks the heart.
- Trial name
- SOTERIA (NCT07218029)
- Testing
- Sotatercept
- Where
- 137 sites in United States, Argentina and 25 more
- Volunteers
- 815 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Arterial Hypertension, Cardiovascular Diseases
Effects of Different Types of Physical Training in Patients With Pulmonary Arterial Hypertension.
Although there has been some progress in pharmacological management of PAH, limited functional capacity and low survival still persist, but there is evidence that exercise training can be accomplished without adverse effects or…
- Conditions
- Pulmonary Arterial Hypertension, Cardiovascular Diseases, Respiratory Disease, Hypertension, Pulmonary
- Trial name
- PAH (NCT03476629)
- Testing
- Physical activity
- Where
- Brazil
- Volunteers
- 45 people
- Sponsor
- University of Nove de Julho
Pulmonary Arterial Hypertension
Lidocaine Subcutaneous Infusion for Control of Treprostinil Related Site Pain
Treprostinil subcutaneous (under the skin) infusion is a very good medication for treating pulmonary arterial hypertension but infusion site pain may be very severe in some patients.
- Trial name
- NCT01433328
- Testing
- Lidocaine
- Where
- Canada
- Volunteers
- 4 people
- Sponsor
- Jewish General Hospital
Pulmonary Arterial Hypertension
6R-BH4 Pulmonary Arterial Hypertension Study
The purpose of this study is to determine whether the addition of sapropterin dihydrochloride (6R-BH4) to existing treatment has any effect in patients with pulmonary arterial hypertension (PAH).
- Trial name
- NCT00435331
- Testing
- sapropterin dihydrochloride (6R-BH4)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Vanderbilt University
Hypertension, Pulmonary
Evaluate the Efficacy, Safety and Pharmacokinetics of GSK1325760A in the Treatment of Pulmonary Arterial Hypertension
The primary objective of this study is to evaluate the effect of GSK1325760A on improvement in exercise capacity in subjects with pulmonary arterial hypertension (PAH).
- Trial name
- NCT00540436
- Testing
- GSK1325760A
- Where
- 15 sites in Japan
- Volunteers
- 25 people
- Sponsor
- GlaxoSmithKline
Pulmonary Arterial Hypertension
Implantable System for Remodulin Post-Approval Study
The purpose of the Implantable System for Remodulin (ISR) Post Approval Study (PAS) is to provide evaluation and periodic reporting of the safety and effectiveness of Medtronic market-released ISR, including the catheter and the…
- Trial name
- ISR PAS (NCT03833323)
- Testing
- Implantable System for Remodulin (treprostinil)
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Pulmonary Arterial Hypertension, Acute Respiratory Failure
Efficacy and Safety of High-Flow Nasal Cannula Versus Noninvasive Ventilation for Pulmonary Arterial Hypertension-Associated Acute Respiratory Failure
This is a single center, retrospective, propensity score matching cohort study that explores the efficacy and safety of high flow nasal cannula and non-invasive ventilation in the treatment of acute respiratory failure associated…
- Conditions
- Pulmonary Arterial Hypertension, Acute Respiratory Failure, High-flow Nasal Cannula, Noninvasive Ventilation
- Trial name
- HFCNV-PAH (NCT06582459)
- Testing
- HFNC treatment, NIV treatment
- Where
- China
- Volunteers
- 90 people
- Sponsor
- The First People's Hospital of Neijiang
Chronic Right-Sided Heart Failure, Pulmonary Arterial Hypertension
Spironolactone Therapy in Chronic Stable Right HF Trial
The purpose of this study is to evaluate the safety, tolerability and mechanistic effects of spironolactone, an aldosterone receptor antagonist, on sympathetic nervous system activity and right heart function and remodeling in…
- Conditions
- Chronic Right-Sided Heart Failure, Pulmonary Arterial Hypertension, Pulmonary Hypertension, Primary, 2, Pulmonary Hypertension, Primary, 3
- Trial name
- STAR-HF (NCT03344159)
- Testing
- Spironolactone, PET/CT Scan: Two PET scans using 1. C-11 HED and 2. N-13 Ammonia or rubidium-82, Cardiac MRI (Gadolinium enhanced)
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Hypertension, Pulmonary
Rapid Switch From Flolan to Remodulin in the Outpatient Clinic
The purpose of this 8-week study is to compare the effects of switching from therapy with epoprostenol or Flolan to IV Remodulin.
- Trial name
- NCT00643604
- Testing
- treprostinil sodium
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension
A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance Imaging
The purpose of the study is to assess the effects of selexipag on right ventricular (RV) function in participants with Pulmonary arterial hypertension (PAH).
- Trial name
- RESTORE (NCT04435782)
- Testing
- JNJ-67896049
- Where
- 35 sites in United States, Argentina and 13 more
- Volunteers
- 9 people
- Sponsor
- Actelion
Pulmonary Vascular Disease, Pulmonary Arterial Hypertension
Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry
Patients are being asked to be in this research study because medical researchers hope that by gathering information about a large number of children with pulmonary hypertension over time, their understanding of the disease…
- Trial name
- PPHNet (NCT02249923)
- Where
- 14 sites in United States, Canada
- Volunteers
- 2,500 people
- Sponsor
- New York Medical College
Pulmonary Arterial Hypertension
A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension
This is a multi-center, open-label study of sitaxsentan sodium 100 mg taken orally once daily by subjects with PAH until sitaxsentan, in a particular country or region, is commercially available for the treatment of PAH or the…
- Trial name
- STRIDE-3 (NCT00811018)
- Testing
- Sitaxsentan
- Where
- 91 sites in United States, Argentina and 14 more
- Volunteers
- 1,192 people
- Sponsor
- Pfizer
Pulmonary Hypertension, Schistosomiasis
Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a severe, progressive and potentially fatal disease that impairs the pulmonary circulation and leads to right ventricular failure.
- Trial name
- SELSCH (NCT04589390)
- Testing
- Selexipag
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- University of Sao Paulo General Hospital
Pulmonary Arterial Hypertension
3D Imaging: Prognostic Role in Pulmonary Arterial Hypertension
Pulmonary hypertension is a rare and severe disease, affecting a young population. Survival is very poor and has been closely related to right ventricular dysfunction.
- Trial name
- HTP3S (NCT02799979)
- Testing
- 3D right ventricular imaging echocardiographic
- Where
- France
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Nice
Pulmonary Arterial Hypertension
Positioning Imatinib for Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension (PAH) is a rare condition in which a narrowing of blood vessels carrying blood through the lungs puts an increased work load on the heart; it has to work harder to pump blood through the lungs.
- Trial name
- PIPAH (NCT04416750)
- Testing
- Imatinib Mesylate
- Where
- 4 sites in United Kingdom
- Volunteers
- 17 people
- Sponsor
- Imperial College London
Pulmonary Hypertension
Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation
This pilot, non-interventional, company-sponsored, multi-center study documents observational data on patients under routine treatment of Pulmonary Arterial Hypertension (PAH) with inhaled iloprost (using I-Neb device for the…
- Trial name
- COMPHI (NCT01894035)
- Testing
- Iloprost (Ventavis, BAYQ 6256)
- Where
- Portugal
- Volunteers
- 13 people
- Sponsor
- Bayer
Pulmonary Arterial Hypertension (PAH), Sleep-disordered Breathing (SDB)
PAH-SDB: Sleep-Disordered Breathing and Outcomes in Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a progressive pulmonary vascular disease characterized by increased pulmonary vascular resistance, right ventricular dysfunction, and clinically important morbidity and mortality.
- Trial name
- PAH-SDB (NCT07852403)
- Testing
- Standardized Overnight Sleep and Cardiorespiratory Monitoring
- Where
- China
- Volunteers
- 1,500 people
- Sponsor
- Chinese Pulmonary Vascular Disease Research Group
Pulmonary Arterial Hypertension
Study Performed at Various Medical Centers to Learn More About Survival and Expected Course of Pulmonary Arterial Hypertension, a Type of High Blood Pressure in the Lungs Related to the Narrowing of the Small Blood Vessels in the Lungs
In this study researchers want to learn more about Pulmonary Arterial Hypertension, a type of high blood pressure in the lungs related to the narrowing of the small blood vessels in the lungs (group 1 according to WHO…
- Trial name
- START (NCT03863990)
- Testing
- PAH medication
- Where
- Argentina
- Volunteers
- 104 people
- Sponsor
- Bayer